NYSE:AZNAstraZeneca Stock Price, Forecast & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 27.4% and is now trading at $56.78.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) issued its earnings results on Thursday, July, 30th. The company reported $0.48 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.44 by $0.04. The business had revenue of $6.28 billion for the quarter, compared to analysts' expectations of $6.27 billion. AstraZeneca had a net margin of 8.36% and a return on equity of 37.72%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 earnings per share.
View AstraZeneca's earnings history.

AstraZeneca declared a semi-annual dividend on Friday, July 31st. Investors of record on Friday, August 14th will be given a dividend of $0.45 per share on Monday, September 14th. This represents a yield of 2.5%. The ex-dividend date is Thursday, August 13th.
View AstraZeneca's dividend history.

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were distributed to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

11 brokers have issued 1 year price targets for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's stock price to reach $61.67 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts' price targets for AstraZeneca.

Media headlines about AZN stock have been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about AstraZeneca.

AstraZeneca saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 8,970,000 shares, an increase of 14.4% from the February 13th total of 7,840,000 shares. Based on an average trading volume of 3,080,000 shares, the days-to-cover ratio is presently 2.9 days.
View AstraZeneca's Short Interest.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Zoetis (ZTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), AT&T (T), Advanced Micro Devices (AMD), Moderna (MRNA) and Cisco Systems (CSCO).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.49%), Fisher Asset Management LLC (0.64%), Raymond James & Associates (0.05%), Hardman Johnston Global Advisors LLC (0.03%), Thornburg Investment Management Inc. (0.03%) and Russell Investments Group Ltd. (0.03%).
View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Assetmark Inc., Russell Investments Group Ltd., Hardman Johnston Global Advisors LLC, Janney Capital Management LLC, ZWJ Investment Counsel Inc., Synovus Financial Corp, Candriam Luxembourg S.C.A., and PNC Financial Services Group Inc..
View insider buying and selling activity for AstraZeneca.

AZN stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Jennison Associates LLC, James Investment Research Inc., Raymond James & Associates, CWM LLC, Trillium Asset Management LLC, Trexquant Investment LP, and Seascape Capital Management.
View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $56.78.

AstraZeneca has a market capitalization of $149.01 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]